2
Jul
2019

Cancer Survivor and Cancer Drug Developer: Laura Shawver on The Long Run

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.

 
 

You may also like

Assembling Accurate Genomes and Interactomes: Ivan Liachko on The Long Run
Restoring Eyesight in the Developing World: Dr. Sanduk Ruit on The Long Run
Bringing Precision Medicine to Neuro: Ivana Magovcevic-Liebisch on The Long Run
Rethinking Biotech Manufacturing: Rahul Singhvi on The Long Run